Drug intelligence / Profile preview

Bifidobacterium bifidum NCDO 2203

Development stage: Unknown
Lead developer: Evidence Based Probiotics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium bifidum NCDO 2203 is a specific strain of probiotic bacteria. It is a key active ingredient in the combination product Infloran®, where it is paired with Lactobacillus acidophilus. [21, 24] This live biotherapeutic product works by colonizing the gut, helping to restore a healthy intestinal microbiome, supporting gastrointestinal immune function, and providing a barrier against pathogenic bacteria. [34, 38] It is primarily used in neonatal intensive care units (NICUs) for the prevention of necrotizing enterocolitis (NEC) and late-onset sepsis in premature or low-birth-weight infants. The contents of the capsule are typically mixed with breast milk, formula, or other liquids for oral administration. [21, 25]

Beyond the preview

Go deeper on Bifidobacterium bifidum NCDO 2203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium bifidum NCDO 2203.

Explore the full profile